Published: Jun 01, 2021
June 1, 2021 11:00 UTC
Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and
in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in
Nature Communications that reports
preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA
in vivo.
The study, “Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo” was led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine, with Ugne Zekonyte as first author.
Search jobs 01-Jun-2021 Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021
DURHAM, N.C. (BUSINESS WIRE) Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and
in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in
Nature Communications that reports
preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA
by WRAL TechWire June 1, 2021 .
DURHAM – Applications of the ARCUS® genome editing platform, a proprietary technology from Durham-headquartered Precision BioSciences, were studied in research now published online by Nature Communications. The study demonstrated the technology may be used to edit outside of the nuclear genome.
The paper, “Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo” was led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine, with Ugne Zekonyte as first author, reports preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.